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ABSTRACT: A novel method was developed and optimized to measure the in vitro release (IVR) of two liposomal ciprofloxacin formulations
under development to treat lung infection. The release agent, bovine serum, has components that interact with liposomes to cause the
encapsulated drug to be released. The precision and accuracy of the method were characterized. The method has a nearly linear release
phase initially, which then approaches a plateau value after 2–4 h. The robustness of the method was verified over a range of release agent
and liposomal concentrations, and in response to changes in incubation temperature, buffer pH, and storage containers of serum. For this
“sample and separate” IVR method, there is less than 2% release at the T = 0 time point, indicating negligible artifactual release before
analysis. For both inhaled liposomal ciprofloxacin products, the plateau value represents 100% release of the encapsulated drug. The key
elements of this IVR method may prove useful for characterization of other liposomal products as well. C© 2013 Wiley Periodicals, Inc. and
the American Pharmacists Association J Pharm Sci 103:314–327, 2014
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INTRODUCTION
Liposome-formulated drugs can provide a number of compelling
advantages over treatment with the unencapsulated drug, in-
cluding the ability to target specific cells or tissues, promote in-
tracellular uptake, improve the safety profile, and reduce side
effects. Traditionally, the primary motivation is to modify the
drug’s release profile.1,2 Liposomes are phospholipid vesicles
composed of one or more lipid bilayers surrounding an aqueous
core and can vary in size ranging from approximately 20 nm to
10 :m. In addition to phospholipids, liposomes can also incorpo-
rate surfactants or cholesterol to alter the membrane rigidity,
and surface modification with polyethylene glycol or antibodies
to produce “stealth” liposomes or to target specific receptors, re-
spectively. When designing a liposomal formulation, one should
consider the route of delivery (e.g., inhalation, injection, infu-
sion), the frequency of administration (e.g., once per day) and
the desired in vivo release rate to ensure that drug levels re-
main within the “window” of adequate therapeutic effects and
safety. The focus of this paper is on in vitro methodology to
characterize the release rate of drug from liposomes; the two
liposomal ciprofloxacin formulations used to characterize this
in vitro release (IVR) method are in late stage clinical develop-
ment to treat lung infections.3–5
The in vivo release rate of drug from liposomal formulations
depends on the design of the liposomal formulation, the route
of delivery into the body including potential interactions be-
tween the liposomal formulation and any delivery technology
that is used, and finally the interaction of the liposomes with
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the fluid and tissue once in the body. With respect to the for-
mulation, the key factors affecting the release rate include the
specific composition and relative proportion of the components
in the vesicles (e.g., surfactants can fluidize the membrane in-
creasing the rate of release, whereas cholesterol can have the
opposite effect), the vesicle size distribution, the lamellarity of
the liposomes (i.e., faster release from unilamellar liposomes),
the nature of the drug (e.g., molecular weight, lipophilicity, and
charge), the physical state of the drug (e.g., precipitated or in
solution), and the release mechanism.6 For inhaled liposomal
formulations, the delivery device can also affect the release
rate. Nebulizers used to generate aerosols have the potential to
disrupt liposomes, causing an increased “burst” of drug, or mod-
ify the liposome vesicle size distribution or lamellarity, which
can also affect the rate of release.2,7 For aerosolized liposomes,
the site of deposition in the lung (e.g., bronchial airways versus
alveolar space) can influence the release rate due to differences
in biological fluid volume and composition. The presence of air-
way disease can confound the situation by influencing the site
of aerosol deposition due to changes in airway dimensions, air-
way patency, and the ability of the patient to correctly inhale
the aerosol. The drug transport rates can also be affected due
to alterations in lung clearance and the composition of the lung
fluid and tissue; for example, mucus and biofilms can interact
with liposomes and impair mucociliary clearance and absorp-
tion.
A qualified IVR assay could be useful during product devel-
opment to provide confidence in the robustness of the liposomal
formulation to changes in manufacturing conditions or during
storage by examining the reproducibility of a key functionality
of the product—rate of drug release. A number of recent work-
shops have been conducted with a focus on defining the current
state of IVR methodology for sustained release pharmaceutical
products including the Controlled Release Society in 20076 and
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the American Association of Pharmaceutical Sciences cospon-
sored with both the FDA and the International Pharmaceutical
Federation (FIP) in 2009.8 Regulatory agencies have also stated
that an IVR test may be useful to assess the properties of li-
posomal products (United States Food and Drug Association
Draft Guidance on Liposome Drug Products, 2002).9
A number of IVR methods have been evaluated for liposome-
encapsulated compounds in the published literature and most
of them fall into three general categories. The most straight-
forward are the “in situ” methods, which measure the release
of drug in real time using an analytical method which can dif-
ferentiate between encapsulated and released drug in the IVR
sample. For drugs which fluoresce, the change in fluorescence
upon release from the liposomes due to dequenching can be
translated into a drug release rate. In practice, this technique
has mostly been limited to model compounds such as calcein10
and carboxyfluorescein11, but has also been found to be use-
ful for doxorubicin.12,13 The “in situ” IVR methodology has ad-
vantages of rapid data output combined with limited sample
manipulation, but, unfortunately, it is not applicable to most
drugs.
A second category of IVR methods involves membrane dial-
ysis to physically separate the released drug from the encapsu-
lated drug in the IVR vessel. This has been performed in the
standard dialysis mode,14 the reverse dialysis mode,15,16 or us-
ing diffusion cells.17 A dialysis adapter was created for use with
the USP apparatus 4, which demonstrated improved discrim-
inating power and less variability over standard and reverse
dialysis techniques.15 These dialysis-based methods are use-
ful when the rate of release from the liposome is relatively slow
compared with the time frame for the free drug to diffuse across
the membrane. However, even in the presence of surfactant in
the medium, the transfer of 90% of the free drug across the
membrane can take 2 h.16 Thus, these dialysis methods may
not be appropriate for systems where the rate of release of the
drug from the liposomes is comparable to or exceeds the rate of
the drug transport through the dialysis membrane.
A third category of IVR methods involves sampling from the
IVR vessel and using a second method to separate the free drug
from the encapsulated drug followed by drug quantitation. The
separation methods that have been used include chromatog-
raphy (gel-filtration18 or cation exchange19), centrifugation or
filtration. The downside to these methods has historically been
the additional sample manipulation, which can lead to artifacts
including additional drug release during the separation step.
One advantage to the published “sample and separate” methods
is that they have frequently used more physiologically relevant
incubation medium to affect release; for example, plasma or
serum for parenterally administered formulations.
The “sample and separate” IVR method reported in this pa-
per utilizes bovine serum in pH 7.4 buffer as the release agent
and uses centrifugal filtration devices to separate the released
drug from the encapsulated drug. Serum was chosen as the re-
lease agent because there is experience using this agent with
other liposomal systems and the components in serum, which
are responsible for release, may also be representative of the re-
lease mechanisms in lung fluid. The main purpose of this study
is to demonstrate that this IVR method is precise, reproducible
and discriminatory. To this end, the sources of variability have
been characterized, which would allow for subsequent method
validation for the liposomal ciprofloxacin formulations evalu-
ated in this study.
MATERIALS AND METHODS
Materials
Lipoquin R©, liposomal ciprofloxacin for inhalation (CFI), empty
liposomes, and free ciprofloxacin (FCI), 20 mg/mL in an acetate-
buffered aqueous formulation at pH 3.3, were provided by
Aradigm Corporation (Hayward, California). Pulmaquin R©, dual
release ciprofloxacin for inhalation (DRCFI), is an equivolume
mixture of CFI and FCI. Donor Adult Bovine Serum was ob-
tained from HyClone (Logan, Utah). Polysorbate 80 was a gift
of Croda, Inc. (Edison, New Jersey). HEPES, free acid was pur-
chased from Avantor (Center Valley, Pennsylvania). Sodium
chloride was purchased from Amresco (Solon, Ohio). Sodium ac-
etate was purchased from Sigma–Aldrich (St. Louis, Missouri).
HPLC grade methanol was purchased from Fisher Scientific
(Fair Lawn, New Jersey) and triethylamine (TEA) was pur-
chased from JT Baker (Center Valley, Pennsylvania) . Nanosep
centrifugal filtration devices, 10K and 30K molecular weight,
were obtained from Pall Corporation (Ann Arbor, Michigan).
Deionized water was used for all studies.
Preparation of Lipoquin (CFI)
The details of the preparation of Lipoquin have been reported
previously.20–22 Briefly, hydrogenated soy phosphatidylcholine
and cholesterol in a 7:3 ratio (by weight) were dissolved in a
t-butanol:ethanol:water mixture (49:49:2) and agitated at 70◦C
for 1 h to ensure complete dissolution. This preparation was
subsequently mixed 1:10 (by volume) with 500 mM ammonium
sulfate and agitated at 70◦C to form multilamellar liposomes.
The multilamellar vesicles were extruded through 80 nm poly-
carbonate filters to yield unilamellar liposomes, approximately
80 nm in diameter. The solvents were removed by diafiltra-
tion with ten volumes of 5 mM histidine, 145 mM NaCl, pH
6.0 buffer. Ciprofloxacin was added to the unilamellar lipo-
somes at 50◦C and the preparation was agitated to facilitate
active loading of drug.21 After loading and removal of unen-
capsulated ciprofloxacin by diafiltration with 25 mM histidine,
145 mM NaCl, pH 6.0 buffer, greater than 99% of the
ciprofloxacin was encapsulated, at a target concentration of
50 mg/mL total ciprofloxacin, expressed as ciprofloxacin hy-
drochloride, and 100 mg/mL total lipids. Empty liposomes were
manufactured with a comparable size and composition to CFI,
but without loading of drug.
EXPERIMENTAL METHODS
Recovery of Free Drug from Nanosep Centrifugal Devices
and Selection of the Centrifugation Time
Nanosep centrifugation devices were used to separate the free
ciprofloxacin from the liposomally encapsulated drug (Fig. 1).
In preliminary experiments, membrane filters with 10,000 and
30,000 molecular weight cutoffs were found to retain the li-
posomes without causing artifactual leakage of encapsulated
drug. For control CFI samples, less than 1% of free drug was
recovered in the filtrate, consistent with greater than 99% of
the drug being encapsulated. Samples from the IVR assay were
expected to contain increasing amounts of free drug after longer
incubation times and so control experiments were conducted to
confirm that the released “free” ciprofloxacin can be quantita-
tively recovered in the filtrate. Three control experiments were
performed using a centrifugation time of 18 min: FCI diluted
DOI 10.1002/jps.23795 Cipolla et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:314–327, 2014
316 RESEARCH ARTICLE – Pharmaceutical Nanotechnology
NN
NH
O
OH
F
O
Ciprofloxacin structure 
Filtrate containing free 
ciprofloxacin (red dots)  
IVR sample containing 
encapsulated and free 
ciprofloxacin in serum  
Centrifuge for 10 min at 
10,000 rpm (8100g)
Membrane filter 
Figure 1. Schematic of the use of the centrifugation filters to separate free ciprofloxacin from the IVR mixture. The IVR samples composed
of free ciprofloxacin (red dots) and liposome-encapsulated ciprofloxacin (blue circles containing red dots) in serum are aliquoted (400 :L) into
filtration devices and centrifuged at 10,000 rpm (8100 g) for 10 min. After centrifugation, the encapsulated drug is retained above the membrane
filter, whereas the free drug in the filtrate can be subsequently quantified.
into HEPES buffered saline (HBS: 20 mM HEPES, 145 mM
NaCl, pH 7.4) to determine the recovery in the absence of lipo-
somes or serum, FCI in HBS buffer diluted 1:1 with serum to
determine if the serum interferes with the recovery, and FCI
and empty liposomes in HBS diluted 1:1 with serum to de-
termine if the combination of liposomes and serum affects the
recovery of free drug. All samples were further diluted 1:1 with
HBS buffer before filtration recovery of free drug to improve
the filterability. In all three studies, five free drug concentra-
tions were evaluated in triplicate, 0.125, 0.5, 2.5, 6.25, and
12.5 :g/mL (to cover the range of 1%, 4%, 20%, 50%, and
100% drug release, respectively). In the third study, the amount
of liposomes added was identical to the amount of liposomes
present in CFI when diluted to 25 :g/mL ciprofloxacin, the
standard concentration in the IVR assay, before the final 1:1
dilution with HBS buffer to aid in the filtration recovery step.
The third control experiment was then repeated across a range
of centrifugation times: 5, 10, 12, 15, and 18 min, to determine
if a shorter centrifugation time could be used, which would still
lead to acceptable and repeatable recovery of free drug.
IVR Methodology
The IVR assay is designed to measure the release of encapsu-
lated drug, in this case ciprofloxacin, from a liposomal prepa-
ration over a period of time that is convenient for analysis; for
example, 2–4 h. Exploratory studies using a range of liposomal
ciprofloxacin concentrations and percent serum were conducted
to identify target values which resulted in 100% release over 2–
4 h incubation at 37◦C. Target values of 25 :g/mL ciprofloxacin
and 50% serum were identified (data not shown). Liposomal
ciprofloxacin samples, either CFI or DRCFI, were diluted to
50 :g/mL ciprofloxacin with HBS and chilled at 2◦C–8◦C be-
fore assay. The 50 :g/mL ciprofloxacin in HBS preparation
was mixed one-to-one with chilled (2◦C–8◦C) bovine serum and
placed in a shaking water bath [Techne, TSBS40 (Staffordshire,
UK)] at 37◦C and 150 rpm to initiate the release of drug. While
the T = 0 samples remained at 2◦C–8◦C, the other time point
samples were loaded into the 37◦C water bath. Samples, typi-
cally in triplicate, were removed periodically; for example, 30,
60, 120, and 240 min, and immediately placed in an ice-water
bath to terminate any further release of encapsulated drug from
the liposomes. These chilled 25 :g/mL ciprofloxacin samples
(including the T = 0 samples) were then diluted 1:1 with chilled
HBS to 12.5 :g/mL ciprofloxacin to reduce the concentration of
serum proteins and liposomes. This step prepares the solution
for filtration by reducing the load on the filter. The rate of filtra-
tion is faster for more dilute solutions and increases the volume
of permeate recovered during centrifugation. An even larger di-
lution step would have the potential to improve the filterability
even further but would increase the analytical challenges of
quantifying a more dilute concentration of ciprofloxacin. Thus,
the 1:1 dilution step was chosen to balance these competing
considerations. To separate the “released” ciprofloxacin from
the liposome-encapsulated ciprofloxacin, 400 :L of each chilled
sample was transferred to a Nanosep centrifugal device and
centrifuged at 10,000 rpm (8100g) for 10 min. The filtrate was
removed for subsequent quantitation of the released or ’free’
ciprofloxacin by HPLC. The original sample was diluted into
80% methanol to dissolve the liposomes and allow for quantita-
tion of the total amount of ciprofloxacin by HPLC. The percent
release was calculated by comparing the free drug to the total
drug in each sample.
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Characterization of the Accuracy and Precision of the IVR Assay
The IVR profiles for both CFI and DRCFI were character-
ized using the standard IVR conditions described above in the
IVR Methodology. Both CFI and DRCFI were diluted with HBS
buffer and bovine serum to a final concentration of 25 :g/mL
ciprofloxacin and 50% serum. In order to measure the IVR
method precision, six replicates of each sample were evaluated
at each time point: T = 0, 30, 60, 120, and 240 min. The inter-
mediate precision of the IVR assay was evaluated by repeating
the experiment using two different analysts on each of 3 days.
Robustness: Effect of Ciprofloxacin Concentration
on the IVR Profile
The target concentration after dilution was 25 :g/mL
ciprofloxacin in the IVR assay for both the 50 mg/mL CFI and 35
mg/mL DRCFI formulations. Typical drug products have spec-
ification limits on the active drug concentration of ±5% and
±10% at release and on stability, respectively. Thus, acceptable
product could vary by up to ±10% around the target concentra-
tion in the IVR assay, in this case, 25 :g/mL ciprofloxacin. The
IVR profiles for CFI at 22.5, 25.0, and 27.5 :g/mL ciprofloxacin
concentration were characterized using the standard IVR con-
ditions described in IVR Methodology. Three replicates of each
sample were evaluated at each time point: T = 0, 30, 60, 120,
and 240 min. A wider range of ±25% of the target concentration
(18.75, 25.0, and 31.25 :g/mL) was also evaluated for both CFI
and DRCFI in order to understand the sensitivity of the IVR
assay to larger variations in drug concentration.
Robustness: Effect of Percent Serum on the IVR Profile
The addition of bovine serum caused release of encapsulated
drug in the IVR assay in a concentration dependent manner
(data not shown). Based on exploratory studies, a value of
50% serum was selected to yield 100% release of encapsulated
ciprofloxacin in a time period of 2–4 h. Additional IVR exper-
iments were conducted to evaluate the effect of a deviation in
the serum concentration by ±2% (of target) to account for typ-
ical laboratory variability; for example, due to pipetting. The
IVR profiles for CFI using 49%, 50%, and 51% serum were
characterized using the standard IVR conditions described in
IVR Methodology. Three replicates of each sample were eval-
uated at each time point: T = 0, 30, 60, 120, and 240 min. A
wider range of ±20% of the target value (40%, 50%, and 60%
serum) was also evaluated for both CFI and DRCFI in order to
understand the sensitivity of the IVR assay to larger changes in
serum concentration. The initial rate of release, T30 min − T0 min,
was defined as the amount of released drug at the 30 min time
point minus that present at the initial time point.
Robustness: Effect of HBS pH on the IVR Profile
The target pH for the HBS buffer in the IVR assay is 7.4.
The effect of variation in the HBS buffer pH was examined
for deviations of ±0.2 pH unit: 7.2, 7.4, and 7.6. The IVR pro-
files for both CFI and DRCFI at 25 :g/mL ciprofloxacin were
characterized using the standard IVR conditions described in
IVR Methodology. Three replicates of each sample were evalu-
ated at each time point: T = 0, 30, 60, 120, and 240 min. For
CFI only, a narrower pH range of 7.3, 7.4, and 7.5 was also eval-
uated in order to understand the sensitivity of the IVR assay
to smaller changes in the HBS buffer pH.
Robustness: Effect of Incubation Temperature on the IVR Profile
The target incubation temperature in the IVR assay is 37◦C.
While the temperature of the shaking water bath can be con-
trolled to 0.1◦C, it is important to understand the effect of tem-
perature variations on the IVR profile. Thus, the IVR assay was
repeated at 35◦C, 37◦C, and 39◦C. The IVR profiles for both CFI
and DRCFI at 25 :g/mL ciprofloxacin were characterized us-
ing the standard IVR conditions, except for the variation in the
incubation temperature. Three replicates of each sample were
evaluated at each time point: T = 0, 30, 60, 120, and 240 min.
Robustness: Effect of Different Serum Containers
on the IVR Profile
Each 500 mL serum container was subaliquoted into 10 mL
plastic vials and stored frozen at −20◦C before use. These
serum containers were all from one batch of serum; contain-
ers of serum from a different batch were not available when
the purchase was made. It is expected that the “activity” of
serum may vary across batches of serum, or even across differ-
ent 500 mL containers from the same batch of serum. While
this source of variability can be mitigated to some extent by
ordering multiple containers of serum from a single serum lot,
mixing them together to homogeneity, and freezing the serum
in small aliquots in plastic vials until needed, thought must be
given to how to transition from one batch to another, even if the
variability across containers in one batch is acceptable. To un-
derstand the variability in serum “activity,” samples of serum
from four individual containers from the same serum batch,
numbered 256, 257, 282, and 283, were evaluated in the IVR
assay. The IVR profiles for both CFI and DRCFI at 25 :g/mL
ciprofloxacin concentration were characterized using the stan-
dard IVR conditions described in the IVR Methodology. Three
replicates of each sample were evaluated at each time point:
T = 0, 30, 60, 120, and 240 min.
Additional Characterization of the Discriminatory Ability
of the IVR Assay
While CFI and DRCFI differ in the amount of ciprofloxacin
present in the formulations, the liposomal compositions are
identical. To evaluate if the IVR assay can discriminate be-
tween different liposomal compositions, CFI was diluted to 12.5
mg/mL ciprofloxacin in 0.2% polysorbate 80 and equilibrated for
30 min to allow for the surfactant molecules to associate with
the liposomes. The IVR assay was performed with a CFI and
DRCFI control, and a further CFI control which was diluted
with serum containing polysorbate 80. This second control CFI
sample had an equivalent amount of surfactant to the experi-
mental CFI sample, 0.0004% polysorbate 80 after final dilution,
and thus could determine whether the presence of surfactant
in the release agent at this level alters the release rate. All
samples were diluted with HBS to 25 g/mL ciprofloxacin be-
fore mixing with serum. Two replicates of each sample were
evaluated at each time point: T = 0, 20, 40, 60, 90, 120, and
240 min.
Ciprofloxacin Quantitation
The amount of ciprofloxacin in each sample was quantified us-
ing an HPLC method as described previously.23 Briefly, HPLC
was performed using a Nucleosil C-18 column (5 :m, 4.6 ×
150 mm2; Canadian Life Science (Peterborough, Ontario)) pro-
tected with a Nucleosil C-18 guard column (4 × 3.0 mm2;
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Phenomenex (Torrance, California)) both at 35◦C. The mobile
phase was a mixture of 0.5% TEA in water, pH 3.0 and 100%
methanol (83:17, v/v) and the isocratic elution was performed
at a flow rate of 0.9 mL/min. Ciprofloxacin was detected at a
wavelength of 277 nm.
RESULTS
Recovery of Free Drug from Nanosep Centrifugal Devices
In the absence of serum or liposomes, the recovery of free drug
ranged from 102% to 106% over the 100-fold concentration
range for both the 10K and 30K filtration devices, indicating
that there is no hold-up of free drug across the membrane filter
(Table 1, Group 1). In the presence of serum, the recovery was
slightly lower ranging from 93% to 99% and 96% to 100% for
the 10K and 30K filtration devices, respectively (Table 1, Group
2). In the presence of empty liposomes and serum, the mean
recovery was approximately 95% for both the 10K and 30K
filtration devices with an overall range of 89%–99% (Table 1,
Group 3A). The recovery of free drug using this procedure ap-
peared to be independent of free drug concentration except for
the lowest concentration condition, which had a slightly lower
recovery. However, this small error would not have a meaning-
ful impact on calculation of release values as the lowest concen-
tration, 0.125 :g/mL, equates to only 1% release from the target
25 :g/mL value after 1:1 dilution with HBS.
The recovery of free ciprofloxacin in the presence of empty
liposomes and serum was repeated for various centrifugation
times, ranging from 5 to 18 min, to determine if a shorter cen-
trifugation time would be acceptable (Table 1, Group 3B). The
recovery was close to 95% for centrifugation times between 10
and 18 min but was slightly lower for the 5 min centrifugation
time. Thus, a centrifugation time of 10 min was selected for in-
corporation into the standard IVR procedure. To correct for this
small but reproducible loss of free drug in the filtration devices,
the free drug concentration in each IVR sample is normalized
by dividing by 0.949, the overall mean recovery factor using the
10 min centrifugation time.
Characterization of the Accuracy and Precision of the IVR Assay
The IVR profiles for both CFI and DRCFI were characterized
using the standard IVR conditions described in IVR Method-
ology by two different analysts on each of three separate
days (Figs. 2a and 2b). CFI represents liposomal encapsulated
ciprofloxacin, whereas DRCFI represents approximately 70%
liposomal encapsulated ciprofloxacin and approximately 30%
unencapsulated ciprofloxacin. The mean (±SD) time zero re-
lease values (T0 min) for the six IVR experiments with CFI and
DRCFI were 1.1% (0.3) and 31.4% (1.1), respectively. These re-
sults are close to the expected values of <1% and approximately
30% and indicate that there is negligible additional release of
free drug during the sampling and separation steps prior to
drug quantitation by HPLC. Chilling the samples at 2◦C–8◦C
appears to adequately inhibit further release of free drug be-
fore or during the 10 min centrifugation. Furthermore, these
results confirm that the centrifugation and filtration step does
not damage the liposomes which could lead to significant leak-
age of drug.
The release of drug from CFI and DRCFI in the IVR as-
say proceeds in a nearly linear fashion initially, and eventually
plateaus in a 2–4 h time frame at a value corresponding to com-
plete release of drug for these liposome preparations (Figs. 2a
and 2b). The range in mean release at the 240 min time point
was 97.5%–104.7% (100.9 ± 3.1%, n = 6) for CFI and 97.1%–
103.2% (100.3 ± 2.4%, n = 6) for DRCFI. In addition to having a
time zero point, (T0 min), to characterize any burst, and a plateau
value at 240 min (T240 min) to determine the overall extent of re-
lease, another time point was sought to represent the midpoint
of release. During IVR method optimization, the 30 min time
point (T30 min) was chosen as a “midpoint” value. In character-
ization studies, the rate of release, equal to the slope of the
curve, at the 30 and 40 min time points was 92% and 90%,
respectively, of the rate of release at the 10 min time point,
suggesting that the value of T30 min is also a reasonable esti-
mate of the initial rate of release (data not shown). The 30 min
period is also adequately long to ensure that any variability
in the timing of removal of multiple samples from the incu-
bation bath, and subsequent transfer to an ice water bath to
terminate further reaction will not have a meaningful impact
Table 1. Percent Recovery of Free Drug (Ciprofloxacin) from the Filtrate of the Nanosep Filtration Devices
Ciprofloxacin Concentration (:g/mL)
Filter Type
Centrifuge
Time (min) 0.125 0.5 2.5 6.25 12.5
Overall Mean
Recovery (%)
Group 1 10K 18 105.6 ± 3.3 103.2 ± 0.5 102.2 ± 0.6 103.1 ± 0.6 102.2 ± 0.3 103.3
30K 105.9 ± 0.4 106.4 ± 2.8 101.7 ± 0.4 102.9 ± 0.5 101.9 ± 0.9 103.7
Group 2 10K 18 92.8 ± 0.5 98.5 ± 0.9 95.6 ± 0.1 97.1 ± 0.1 95.6 ± 0.1 95.9
30K 97.1 ± 0.6 99.7 ± 0.5 96.0 ± 0.1 96.8 ± 0.1 96.6 ± 0.1 97.2
Group 3A 10K 18 93.9 ± 0.6 97.6 ± 0.8 95.4 ± 0.4 95.5 ± 0.2 95.7 ± 0.1 95.6
30K 89.3 ± 1.5 99.3 ± 1.4 95.5 ± 0.2 96.2 ± 0.3 96.0 ± 0.1 95.3
Group 3B 30K 5 89.6 ± 2.1 93.1 ± 1.2 92.8 ± 0.3 92.6 ± 0.8 92.9 ± 0.3 92.2
10 93.6 ± 1.6 96.6 ± 0.9 94.3 ± 1.5 94.7 ± 0.1 95.3 ± 0.3 94.9
12 90.4 ± 2.9 96.5 ± 0.3 94.7 ± 0.7 95.3 ± 0.3 95.7 ± 0.4 94.5
15 90.9 ± 3.2 98.7 ± 0.8 96.4 ± 0.2 95.3 ± 0.5 96.8 ± 0.1 95.6
18 89.3 ± 3.2 99.3 ± 1.5 95.5 ± 1.3 96.2 ± 0.2 96.0 ± 0.3 95.3
The recoveries represent mean ± SD of triplicate determinations. Group 1 represents recovery of ciprofloxacin diluted in HBS. Group 2 represents the recovery
of ciprofloxacin in HBS diluted 1:1 with serum and then 1:1 with HBS. Groups 3A and 3B represent the recovery of ciprofloxacin in empty liposomes diluted 1:1 with
serum and then 1:1 with HBS. For Groups 1, 2 and 3A, either 10K or 30K filtration devices were used. For Group 3B, the centrifugation time ranged from 5 to 18 min
for the 30K centrifugation device.
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Figure 2. Evaluation of the intermediate precision of the IVR assay across three nonconsecutive days and two different analysts. Release of
ciprofloxacin from CFI (a) and DRCFI (b) in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37◦C for 4 h. Each
value represents the mean ± SD (n = 6). There was one outlier value removed, according to predefined criteria, out of a total of 360 data points.
The “No Serum Control” sample was diluted into 10 mM HEPES buffered saline, pH 7.4, without serum, and incubated at 37◦C for 4 h (n = 3
per time point).
on the release values. The range in mean release values at
T30 min was 45.3% to 50.7% (48.1 ± 2.1%, n = 6) for CFI and
59.1 to 64.8% (61.8 ± 2.3%, n = 6) for DRCFI. These values
represent release of 47.4% and 44.3%, respectively, of the en-
capsulated drug present at T0 min (98.9% and 68.6% for CFI
and DRCFI, respectively) indicating that T30 min is well chosen
to represent the midpoint and that the rate of release from
both formulations is comparable after the initial burst: While
the initial rate of release is comparable for CFI and DRCFI, the
IVR assay discriminates between the two formulations due to
the 30% “burst”in the DRCFI formulation.
Six replicates were conducted for each sample at each time
point to assess the method precision (repeatability). The repli-
cates were very repeatable with a mean precision of 1.4%, 1.3%,
0.5%, and 0.9% RSD for the 30, 60, 120, and 240 min time
points, respectively, for CFI. The mean precision for DRCFI
was also comparable with values of 1.1%, 1.1%, 0.9%, and 0.7%
RSD at the 30, 60, 120, and 240 min time points, respectively.
The T0 min release values are also very repeatable, in terms of
standard deviation, but because the release values are all close
to zero for CFI it is not sensible to report relative standard devi-
ations. The intermediate precision was evaluated by repeating
the IVR assay using two different analysts on three days to as-
sess the analyst-to-analyst and day-to-day variability (Figs. 2a
and 2b). The day-to-day variability was a greater source of error
than the analyst-to-analyst variability.
A control CFI sample diluted into HBS buffer alone, without
serum, was incubated at 37◦C for 4 h and subjected to the same
“sample and separate” methodology as for the experimental
samples. Only 0.8% additional release of encapsulated drug
was observed over the 4 h incubation (Fig. 2a) demonstrating
that serum is required for release. This result also confirms
that there is negligible nonspecific release due to the “sample
and separate” methodology itself; that is, incubation for 4 h at
37◦C in pH 7.4 HBS buffer followed by the centrifugal filtration
processing step.
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Figure 3. Evaluation of the effect of changes in ciprofloxacin concentration on the IVR assay. The release of (a) 22.5, 25, and 27.5 :g/mL
ciprofloxacin from CFI and (b) 18.75, 25, and 31.25 :g/mL ciprofloxacin from CFI and DRCFI in 50% bovine serum and 10 mM HEPES buffered
saline, pH 7.4 after incubation at 37◦C for 4 h. Each value represents the mean ± SD (n = 3). There were no outlier values out of a total of 135
data points.
Robustness: Effect of Ciprofloxacin Concentration
on the IVR Profile
In order to evaluate the robustness of the assay to changes in
drug concentration of ±10%, the IVR profiles for CFI at 22.5,
25.0, and 27.5 :g/mL ciprofloxacin were characterized (Fig. 3a).
All three profiles were comparable with no meaningful initial
“burst,” followed by a linear release for 30–60 min, which ap-
proached a plateau within 2–4 h corresponding to 100% release
of drug. There was not a meaningful change in the initial re-
lease values over this concentration range with the T30 min val-
ues varying between 43.3%–45.4%. These results suggest that
the acceptable variability in drug concentration, up to ±10%,
that might be expected between vials, across batches or on sta-
bility will not influence the performance in the IVR assay.
A wider range of ±25% of the target ciprofloxacin concen-
tration (18.75, 25.0, and 31.25 :g/mL) was also evaluated for
both CFI and DRCFI (Fig. 3b). The IVR profiles again share
the same features as in Figure 3a with a limited spread in
the T30 min values for CFI (40.6%–43.2%) and DRCFI (58.1%–
61.8%). This suggests that the IVR assay is robust to changes in
the target concentration of up to ±25%. The differences in the
CFI T30 min values between the two sets of data (40.6%–43.2%
vs. 43.3%–45.4%) reflect the day-to-day assay variability. The
highest ciprofloxacin concentration (31.25 :g/mL) does appear
to have a slightly faster rate of release by the 60 min time point
for both CFI and DRCFI but reaches the same plateau value
(T240 min) corresponding to 100% release.
Robustness: Effect of Percent Serum on the IVR Profile
The robustness of the IVR assay to changes in serum concen-
tration of ±2% and ±20% of the target value of 50% serum
are reported in Figures 4a and 4b, respectively. As might be
expected, changes in the serum concentration over both ranges
had no effect on the T0 min value or the overall extent of re-
action as the plateau values all leveled off at approximately
100% release. However, higher serum concentrations resulted
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Figure 4. Evaluation of the effect of changes in serum concentration on the IVR assay. After incubation at 37◦C for 4 h, the release of 25 :g/mL
ciprofloxacin from (a) CFI in 49%, 50%, and 51% bovine serum and 10 mM HEPES buffered saline, pH 7.4 and (b) CFI and DRCFI in 40%, 50%,
and 60% bovine serum and 10 mM HEPES buffered saline, pH 7.4. Each value represents the mean ± SD (n = 3). There were no outlier values
out of a total of 135 data points. (c) The initial release rate, equivalent to the release value for T30 min – T0 min, is plotted versus the percent serum
for both CFI and DRCFI.
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Figure 5. Evaluation of the effect of changes in the pH of HEPES
buffered saline (HBS) on the IVR assay. The release of 25 :g/mL
ciprofloxacin from (a) CFI in 50% bovine serum and 10 mM HBS, pH
7.3, 7.4, and 7.5 and (b) CFI and DRCFI in 50% bovine serum and
10 mM HBS, pH 7.2, 7.4, and 7.6 after incubation at 37◦C for 4 h. Each
value represents the mean ± SD (n = 3). There were no outlier values
out of a total of 135 data points.
in a faster initial rate of release and an earlier plateau, whereas
lower serum concentrations resulted in slower initial rates and
a later plateau for CFI and DRCFI (Fig. 4b). For small varia-
tions in serum of ±2% that might be expected during routine
use of the IVR assay, the change in the T30 min values was rel-
atively small, ranging from 44.1% to 47.1% release for CFI,
similar to the spread in T30 min values due to day-to-day as-
say variation (section IVR Methodology). The initial reaction
rate, T30 min – T0 min, is directly proportional to the concentra-
tion of serum used in the assay over the 40%–60% serum range
(Fig. 4c).
Robustness: Effect of HBS pH on the IVR Profile
A deviation of 0.1 pH unit in the HBS buffer from the 7.4 target
value resulted in changes in the release values for CFI at T30 min
(Fig. 5a) that exceeded the day-to-day assay variability (Fig. 2):
the range in the T30 min values was 43.7%–55.6% with the lowest
release at pH 7.3 and the highest release at pH 7.5. There was
no effect on the “burst” value at T0 min, or the plateau value of
100% release at T240 min. However, the lower buffer pH resulted
in a delay in the time to reach the plateau. This finding was also
confirmed for DRCFI over the HBS buffer pH range of 7.2–7.6
with the lower HBS buffer pH (7.2) having a greater degree of
impact on the initial rate of release than the higher buffer pH
(7.6) (Fig. 5b).
Robustness: Effect of Incubation Temperature on the IVR Profile
While the target IVR incubation temperature is 37.0◦C, and the
shaking water bath temperature set-point can be controlled to
0.1◦C, if the assay is conducted across multiple labs using dif-
ferent shaking water baths the actual temperature may vary
to a greater degree. Thus, it is important to understand the
effect of incubation temperature on the performance of the IVR
assay. The effect of a ±2◦C change in incubation temperature
on the IVR profile is shown in Figure 6a for both CFI and DR-
CFI. Changing the temperature did not affect the “burst” value
(T0 min), as would be expected as these samples were not placed
in the water bath, or the ultimate extent of release (T240 min) for
either formulation. However, the rate of release was acceler-
ated by an increase in temperature and reduced by a decrease
in temperature from the target value of 37.0◦C. For CFI, the
initial rate of release, T30 min − T0 min, was 28.5, 44.0, and 68.8%
ciprofloxacin at 35◦C, 37◦C, and 39◦C, respectively. For DRCFI,
the initial release rate, T30 min − T0 min, was lower due to the
“burst” at time zero: 18.4%, 28.7%, and 41.0% ciprofloxacin at
35◦C, 37◦C, and 39◦C, respectively. The initial rate of release
of ciprofloxacin from both the CFI and DRCFI formulations is
consistent with Arrhenius kinetics over the 35◦C–39◦C temper-
ature range as shown in Figure 6b. The values for the slopes
were within 10% of each other (r2 = 0.9999 and 0.9964 for
CFI and DRCFI, respectively). An activation energy of approx-
imately 170 kJ/mol was imputed from the mean slope values.
Robustness: Effect of Different Serum Containers
on the IVR Profile
The IVR activity of serum from four different containers was
evaluated for both CFI and DRCFI (Fig. 7). All four contain-
ers of serum produced comparable IVR profiles with no sig-
nificant changes in the “burst” value (T0 min) or the plateau
value (T240 min) within the variability of the assay, for both CFI
and DRCFI. When comparing the release at T30 min, serum con-
tainer 256 was slightly more active, whereas serum container
257 was slightly less active than containers 282 and 283, for
both CFI and DRCFI. For CFI, the T30 min values were 43.8%
and 40.1% for containers 256 and 257, respectively, compared
with 42.9 and 41.4 for containers 282 and 283, respectively. For
DRCFI, there was a slightly greater spread in the T30 min values
with 70.3% and 60.1% recorded for containers 256 and 257, re-
spectively, versus 65.3% and 65.2% for containers 282 and 283,
respectively. The relative activity of the serum containers is in
the order 256 > 282 = 283 > 257.
Additional Discrimination Across Liposomal Ciprofloxacin
Formulations
CFI and DRCFI only differ in the initial “burst” of drug at T0 min.
Excluding the initial value, the rate of release of ciprofloxacin
was comparable (Fig. 2a vs 2b) as would be expected because
the liposomal composition in CFI and DRCFI are identical. To
evaluate if the IVR assay can differentiate between different
compositions that might be expected to have different release
rates, 0.2% polysorbate 80 was added to 12.5 mg/mL CFI and
allowed to equilibrate for 30 min before dilution into HBS and
serum. After dilution, the final concentration of polysorbate
80 was only 0.0004%. The IVR profile of this formulation was
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Figure 6. Evaluation of the effect of change in incubation temperature on the IVR assay. (a) The release of 25 :g/mL ciprofloxacin from CFI
and DRCFI in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 35◦C, 37◦C, or 39◦C for 4 h is reported. Each
value represents the mean ± SD (n = 3). There were no outlier values out of a total of 90 data points. (b) The natural logarithm (ln) of the initial
release rates (k = T30 min – T0 min) for each of the six curves is plotted versus the inverse of temperature in ◦K.
substantially different from CFI and DRCFI (Fig. 8). The
“burst” (T0 min) increased from <1% (c.f. CFI) to 29% and the
remaining encapsulated drug had a much faster release rate
than for the CFI and DRCFI controls with more than 90%
released after 20 min (Fig. 8). This result could not simply
be explained by the presence of the surfactant in the release
buffer: the IVR profiles for CFI when diluted into serum, with
or without 0.0004% polysorbate 80, were comparable (Fig. 8).
The time points in this IVR experiment were not chosen to
provide a complete IVR profile for the CFI sample containing
surfactant—otherwise earlier time points would have been se-
lected given its faster release profile (e.g., 5 and 10 min); but
instead simply to determine whether the IVR assay can differ-
entiate between the samples.
DISCUSSION
Numerous drugs have been evaluated in liposomes for in-
halation delivery24 and a subset has been delivered to hu-
mans using nebulizers including imaging agents, anti-asthma
drugs, analgesics, immunosuppresives, cytotoxic agents, an-
tifungals, and antimicrobials.1,2 There are now two inhaled
liposomal products in late-stage clinical development target-
ing lung infections, liposomal amikacin (ARIKACE R©; Insmed
(Monmouth Junction, New Jersey)) and liposomal ciprofloxacin
(Pulmaquin R©; Aradigm Corporation). Our goal was to develop
and qualify an IVR assay for the inhaled liposomal ciprofloxacin
formulations in order to have a laboratory assay to assess a
key functional aspect of the product—the rate of drug release.
Therefore, the robustness of the IVR assay was investigated
with respect to the variation of the key parameters of the assay:
drug concentration, serum concentration, buffer pH, incubation
temperature, and serum container.
For intravenously administered liposomal products, it is rea-
sonable to use serum as a release vehicle because the lipo-
somes will be rapidly diluted into serum in the blood stream.
However, it is less clear that serum would be an appropriate
release fluid for products delivered to the lung. It is thus impor-
tant to understand the components in lung fluid which would
likely interact with liposomes and contribute to the release
of encapsulated drug. It is well recognized that lipoproteins
and apolipoproteins in serum can have a destabilizing effect on
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Figure 7. Evaluation of the effect of using different serum containers (#256, 257, 282, and 283) from the same serum batch on the IVR assay.
The release of 25 :g/mL ciprofloxacin from CFI and DRCFI in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at
37◦C for 4 h is reported. Each value represents the mean ± SD (n = 3). There were no outlier values out of a total of 120 data points.
Figure 8. Evaluation of the effect of liposomal composition on the IVR assay. The release of 25 :g/mL ciprofloxacin from CFI, CFI containing
0.0004% polysorbate 80, and DRCFI in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37◦C for 4 h is reported.
An additional control CFI formulation was diluted into 50% bovine serum, 0.0004% polysorbate 80, and 10 mM HEPES buffered saline, pH 7.4.
Each value represents the mean (n = 2). There was one outlier value out of a total of 56 data points.
liposomes causing drug release.11,25 Scherphof et al.18 report
that the phosphatidylcholine in liposomes is found to rapidly
associate with lipoprotein-like particles after incubation with
serum and this correlates with massive destruction of the li-
posome structures and release of drug. Allen and Cleland10
confirmed and expanded on that finding by suggesting that
the presence of cholesterol in the liposomes may inhibit, but
not eliminate, the exchange of phospholipid with high den-
sity lipoprotein. Weinstein et al.11 studied the interaction of
proteins with lipid bilayers and found that most serum pro-
teins did not induce release of encapsulated drug, including
trypsin, albumin and ovalbumin, but that all serum lipopro-
teins and apolipoproteins do induce rapid release. Lipoproteins
and apolipoproteins are also present in lung fluid, but at about
half the concentration in serum.26 So the IVR assay should ide-
ally incorporate those elements into the release medium. Lung
fluid also contains surfactant and lipids, which may also have a
contributory effect. While there are a number of simulated lung
fluid preparations published in the literature, no recognized
standard exists.27 Furthermore, of the six listed preparations,
only one contains lipid and none contain surfactant or lipopro-
teins. Confounding the situation further, there is considerable
variability in the composition of the lung fluid throughout the
lung, and additional variability among individuals, without
even taking into account the presence of disease on lung fluid
composition. Thus, there is not a straightforward choice for
Cipolla et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:314–327, 2014 DOI 10.1002/jps.23795
RESEARCH ARTICLE – Pharmaceutical Nanotechnology 325
release vehicle which simulates the release mechanisms in the
lung. Our goal was to identify a release medium that would
be biological in composition, relatively homogeneous, easy to
obtain, and relevant to the release mechanism in the lung. Pu-
rified lipoprotein or apolipoprotein is not easily obtained but
they are both present in serum. For that reason, bovine serum
was chosen as the release medium.
The studies reported in this paper demonstrate that the se-
lected filtration devices are able to separate free ciprofloxacin
from the serum and liposomes reproducibly with an efficiency
of approximately 95% across a 100-fold range in ciprofloxacin
concentration (Table 1). The liposomes containing encapsulated
ciprofloxacin are not compromised by the centrifugation and fil-
tration process (Fig. 1). The utility of this filtration technique
may be significantly affected by the characteristics of the en-
capsulated agent and therefore may not be broadly applicable
to other liposomal formulations. Its usefulness will need to be
assessed on a formulation by formulation basis. The IVR assay,
which involves incubation with bovine serum to cause release of
encapsulated drug from the liposomes, was also shown to have
good precision and reproducibility. The IVR profiles for our li-
posomal ciprofloxacin formulations are characterized by three
distinct phases of release, the initial “burst” of drug (where
such “burst” was designed into each formulation), followed by
a nearly linear release of drug that proceeds until a majority
of the drug is released (60%–80%), and then a slower release
to reach a plateau value which defines the total extent of re-
lease (Fig. 2). The IVR assay appears to be relatively robust
to changes in ciprofloxacin concentration over a range of ±25%
with respect to quantifying the amount of “burst,” the amount
of drug released after 30 min, and the extent of release (Fig. 3)
making these parameters suitable to monitor the release prop-
erties. The IVR assay is sensitive to intentional changes in the
amount of serum (±20%), with higher serum concentrations
causing an increase in the release rate. However, the normal
variability due to pipette technique (±2%) did not have a mean-
ingful impact on the reproducibility of the assay (Fig. 4).
Changes in the HBS buffer pH had an effect on the release
rate greater than the day-to-day assay variations, with devi-
ations below pH 7.4 having a greater effect than deviations
above pH 7.4 (Fig. 5). It is unclear why relatively small devia-
tions in buffer pH of 0.2 units have a significant influence on
the rate of release. While the exact mechanism is unknown,
the apolipoproteins and lipoproteins in the serum likely inter-
act with the phospholipid in the liposomes to cause release.11
One explanation may be that a change in pH affects the charge
of ionizable groups on these lipoproteins and thus modulates
their affinity for the liposomes or their affinity for each other.
Another explanation may be that the serum lipoproteins in-
crease the permeability of the liposomes, without destroying
their structure, and dissipates the pH gradient across their
liposome bilayers. Only the neutral, uncharged ciprofloxacin
molecules are able to diffuse across the liposome bilayer so the
rate of release could be proportional to the fraction of neutral,
uncharged ciprofloxacin molecules. It is possible that the pro-
portion of neutral, uncharged ciprofloxacin molecules within
the liposomes increases for the pH 7.6 buffer and decreases for
the pH 7.2 buffer. There may be other explanations as well. Re-
gardless of the exact mechanism causing drug release, in order
to minimize this source of variability, it is essential to imple-
ment laboratory procedures to ensure that the HBS buffer pH
is as close to 7.40 as practicable.
While the details of the experiments have not been reported
in this paper, there was no influence of shaking speed over the
range of 100–200 rpm on the IVR assay. A shaking speed of 150
rpm, representing the midpoint of this range, has been used
throughout these studies. In contrast, the incubation tempera-
ture over the range of 35◦C–39◦C does affect the release rate in
line with Arrhenius kinetics indicating that no phase transition
is taking place over this temperature range (Fig. 6). It is un-
known if the liposomes retain their structure in the presence of
serum. Changes in temperature affect the diffusion rate across
biological membranes for large molecules to a greater degree
than for small molecules.28 They report that the activation en-
ergy associated with diffusion of molecules within polyisobuty-
lene increased from 33 to 75 kJ/mol as the diffusant molecular
weight increased from 2 to 72 g/mol. Thus, the imputed ac-
tivation energy of approximately 170 kJ/mol for ciprofloxacin
which, being a larger molecule (MW 368) would require larger
pores to diffuse through, is not inconsistent with this model.
Other explanations are also possible. In any case, to reduce
variability in the IVR assay, for example, across laboratories, it
is thus essential that the temperature control of the water bath
be closely calibrated and monitored.
Each 500 mL container of bovine serum was divided into
10 mL aliquots and stored frozen until the day of use. Serum
samples from all four containers produced similar IVR profiles,
and had comparable effect in terms of the initial rate of release,
T30 min (Fig. 7), but there is no assurance that subsequent con-
tainers from this batch, or containers from a different batch,
will not have larger differences in activity which could be prob-
lematic when transitioning from one container to the next. We
plan to investigate in the future the impact of the variation in
the serum batches on the IVR assay, once they become avail-
able.
For liquid aerosols produced by nebulizers, there is the po-
tential for the aerosol droplets to dry during laboratory collec-
tion, which could disrupt the liposome vesicles, in contrast to
the in vivo situation in which the droplets are unlikely to dry
in the moist and humid environment of the lungs.7 The lipo-
somal ciprofloxacin formulations evaluated in this paper were
also characterized for their stability to the nebulization process
by collecting the aerosol in an SKC BioSampler that prevents
the artifactual drying.23 In addition, the residual solution in
the nebulizer at the end of nebulization was analyzed. Both
were shown to retain the liposome size distribution and drug
encapsulation properties. The IVR profiles of these liposomal
ciprofloxacin formulations were also shown to be unaffected by
nebulization using three different nebulizers.7 Thus, this IVR
method may also be amenable to characterization of liposomal
aerosols if they are collected by a method that does not disrupt
them.
The IVR assay was also shown to be discriminating for three
liposomal ciprofloxacin formulations including two that differed
in the amount of ‘burst’ but had similar release rates (Figs. 2a
vs. 2b) and one with both a different “burst” and release rate
(Fig. 8). The presence of surfactant in the latter liposomal for-
mulation caused an increase in the amount of free drug as well
as an increase in the IVR release rate; however, no change to ei-
ther parameter was observed for CFI when the surfactant was
added to the release medium only. While high surfactant con-
centrations can solubilize liposomes, at lower concentrations
the surfactant can associate with the phospholipid bilayers
of the liposome and lead to increased permeability without
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general loss of structure to the liposome.29 This may explain
the increase in release rate. The increase in “burst” at T0 min
has also been explained by either of two mechanisms: the for-
mation of transient pores during the initial surfactant-liposome
association process which allows some of the encapsulated drug
to escape before the channels close, or the rupture of a subset of
liposomes which results in an increase in free drug.30 The pres-
ence of surfactant in the release medium alone had no effect on
the IVR profile indicating that the surfactant concentration was
too low to compromise the liposome structure or permeability.
While these formulations all approach a plateau by the 2 h time
point, the inclusion of a 4 h time point (T240 min) is to provide
discrimination power for formulations having a slower release
profile which may occur for liposomes with differing composi-
tions from those reported here (unpublished data). This IVR
test may also be useful to compare different batches of product
or after product is aged or subjected to various stress condi-
tions; for example, light, heat, acid, base, temperature cycling,
and so on.
The pharmacokinetic profiles of CFI and DRCFI liposomal
ciprofloxacin formulations have been compared in an inhala-
tion study in healthy subjects and both were found to have a
prolonged systemic uptake, with a half-life of approximately
10 h.31–33 However, the DRCFI formulation also achieved much
higher systemic levels of ciprofloxacin over the first two hours,
consistent with the “burst” of 30% ciprofloxacin observed in the
IVR assay. The in vivo release is longer than the release ob-
served in the IVR assay reported here, which was by intention,
so that the assay would be rapid and convenient. The IVR as-
say could have been designed to more closely simulate the in
vivo release rate by using a lower concentration of serum, or ef-
fecting other changes to the methodology, but that was not the
goal of the present study: to develop and qualify a laboratory
method for routine testing during product development.
CONCLUSIONS
This study describes an accurate and precise IVR method that
has been used to characterize the release of drug from two li-
posomal ciprofloxacin formulations undergoing evaluation in
clinical trials to treat lung infections in cystic fibrosis (CF) and
non-CF bronchiectasis patients. The robustness of the assay
was characterized with respect to changes in: (a) drug concen-
tration, (b) serum (releasing agent) concentration, (c) buffer
pH, (d) incubation temperature, and (e) serum containers. The
IVR profile provides a measurement of the initial “burst” from
the liposomal formulation when it is designed to be present
in the formulation (and observed following administration to
humans), followed by a nearly linear release of drug initially,
ultimately reaching a plateau value representing the full ex-
tent of release. Selection of a convenient time point during the
initial release phase, which is 30 min in the case of these li-
posomal ciprofloxacin preparations, allows for comparison be-
tween different lots of product or product from various tem-
poral stages in its shelf-life, to provide assurance that the
product retains reproducible drug release characteristics. This
method was discriminatory between formulations of liposomal
ciprofloxacin that differed in composition. Although this IVR
assay could be useful in principle for other liposomal products,
its performance may be significantly affected by the charac-
teristics of the drug and the formulation. Its usefulness will
therefore need to be assessed on a formulation by formulation
basis.
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